Key phase 3 and phase 4 trials evaluating the safety and efficacy of sorafenib in advanced HCC
Globally, liver cancer represents a major health care burden, accounting for almost 700,000 deaths annually.  Hepatocellular carcinoma (HCC) comprises 70% to 85% of primary liver cancers in most regions.  Although the incidence of HCC has historically been lower in the US than in many other countries, age-adjusted rates tripled between 1975 and 2005.  In fact, liver cancer is the fastest-growing cause of cancer-related death in American men.  Most patients with HCC are diagnosed at advanced stages and are ineligible for potentially curative treatments such as surgical resection and liver transplantation.  Prior to the introduction of sorafenib in 2007, systemic treatments were unavailable for patients with HCC.
In defining optimal treatment for patients with HCC, several questions remain unanswered. Clinical data are needed to evaluate sorafenib safety in patients with advanced liver disease (i.e., those with Child-Pugh [CP] B disease) and in those with HCC-associated portal hypertension. In addition, how best to utilize sorafenib in combination with sequential locoregional therapies (LRT) or post-surgery remains unclear. These challenges are further compounded by the ongoing uncertainties in determining the value of the modified Response Evaluation Criteria In Solid Tumors (mRECIST) and understanding the optimal timing for response assessment in patients treated with sorafenib and/or LRT. Proactive management of adverse events (AEs) associated with sorafenib also remains an area of active investigation. Finally, although sorafenib has demonstrated a clear benefit to patients with advanced HCC, the majority of patients will ultimately experience disease progression. Efforts are underway to evaluate the best approaches to treating these patients in a manner that minimizes the risk of mortality from deterioration of the underlying liver disease. In this review, we describe the current understanding of sorafenib’s efficacy and safety, and ongoing approaches to defining even better treatment options for patients with HCC.
2. Late-phase clinical development of sorafenib for unresectable, advanced HCC: Pivotal trials and subanalyses
Clinical trial design in HCC is challenging owing to the complex nature of the disease. The coexistence of cancer, liver disease, and other comorbidities, and the prior or concomitant use of locoregional therapies make selection and recruitment of an appropriately homogeneous patient cohort difficult. Geographical heterogeneities in disease etiology, patient characteristics, and practice patterns are significant and contribute to the need for, and confound, multi-institutional studies.
Both pivotal trials of sorafenib, the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) and Asia-Pacific (AP), were designed to elucidate the effect of the drug in a specific population of patients with preserved liver function (CP A). In these trials, sorafenib produced a significant survival advantage over placebo in patients with advanced HCC; these results led to regulatory approval of sorafenib [6,7] (Table 1).
|400 mg BID continuous SOR vs PBO||CP: A, 97%; B, 3%|
BCLC stage: B, 17%, C, 82%
ECOG PS: 0, 54%; 1, 38%; 2, 8%
Hepatitis virus status: HBV, 18%; HCV, 28%
|Median OS: 10.7 mo SOR vs 7.9 mo PBO; HR 0.69 (95% CI 0.55-0.87; |
Median time to symptomatic progression: 4.1 mo SOR vs 4.9 mo PBO;
Median time to radiologic progression: 5.5 mo SOR vs 2.8 mo PBO (
Response, by RECIST (SOR vs PBO):
CR: 0% vs 0%
PR: 2% vs 1% (
SD: 71% vs 67% (
DCR (≥SD for ≥28 days): 43% vs 32% (
|Gr 3/4 drug-related AEs (SOR vs PBO):|
HFSR: 8% vs <1% (
Diarrhea: 8% vs 2% (
Fatigue: 4% vs 3%-4% (
|Randomized 2:1 to 400 mg BID continuous SOR vs PBO||CP: A, 97%; B, 3%|
BCLC stage: C, 96%
ECOG PS: 0, 26%; 1, 69%; 2, 5%
Hepatitis virus status: HBV, 73%; HCV, 8%
|Median OS: 6.5 mo SOR vs 4.2 mo PBO (HR 0.68 [95% CI 0.50-0.93]; |
Median TTP: 2.8 mo SOR vs 1.4 mo PBO (HR 0.57 [95% CI 0.42-0.79];
Response by RECIST (SOR vs PBO):
CR: 0% vs 0%
PR: 3% vs 1%
SD: 54% vs 28%
PD: 31% vs 54%
Not accessible: 12% vs 17%
DCR (≥SD for ≥28 days): 35% vs 16% (
|Gr 3/4 drug-related AEs (SOR vs PBO):|
HFSR: 11% vs 0%
Diarrhea: 6% vs 0%
Fatigue: 3% vs 1%
N=1571 for 2nd interim analysis
|Prospective, non-interventional study of pts with unresectable HCC treated with SOR||CP: A, 61%; B, 23%; C, 2%|
BCLC stage: A, 7%; B, 19%; C, 54%; D, 6%
ECOG PS: 0, 40%; 1, 43%; 2, 9%; 3-4, 3%
HCC etiology: HBV, 37%; HCV, 32%; alcohol, 29%
|Median OS by initial dose:|
400 mg/d: 7.1 mo (95% CI 5.8-8.1)
800 mg/d: 9.3 mo (95% CI 8.6-10.2)
Median TTP by initial dose:
400 mg/d: 3.6 mo (95% CI 2.8-4.1)
800 mg/d: 4.5 mo (95% CI 4.1-5.1)
Median OS by CP status:
A, 10.3 mo; B, 4.8 mo; C, 2.0 mo
Median TTP by CP status:
A, 4.2 mo; B, 3.6 mo; C, 2.1 mo
|Gr 3/4 drug-related AEs:|
Drug-related serious AEs: 9%
AEs leading to SOR discontinuation: 28%
In subanalyses of these pivotal trials, the safety profile of sorafenib was similar regardless of baseline liver function. In the SHARP trial, sorafenib treatment consistently improved overall survival (OS), time to progression (TTP), and disease control rate (DCR) irrespective of Eastern Cooperative Oncology Group performance status (ECOG PS); tumor burden, as evidenced by macroscopic vascular invasion or extrahepatic spread; tumor stage (Barcelona Clinic Liver Cancer [BCLC] stage B or C); prior curative treatments (including surgery, radiofrequency ablation, or percutaneous ethanol injection); or prior transarterial chemoembolization (TACE)  (Figure 1). However, patients with tumors confined to the liver, with no vascular invasion or metastases, had better outcomes. Substantially similar results were obtained in subanalyses of the AP trial, with the exception of patients with ECOG PS 0, who had a slightly reduced OS in the sorafenib treatment group  (Figure 2). In both studies, sorafenib also improved OS over placebo irrespective of baseline serum alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein (AFP), and bilirubin levels. [9, 10] Notably, in the SHARP trial, hepatitis B virus (HBV) surface antigen positivity was associated with a longer median OS but shorter TTP in patients treated with sorafenib; however, DCR was similar in sorafenib- and placebo-treated groups.
It is interesting to note that in the SHARP trial, patients positive for HCV antibody derived more benefit from sorafenib treatment than patients with other etiologies  (Figure 1) Consistent with this notion, preclinical data suggest that sorafenib may inhibit Raf-dependent HCV replication and HCV-induced increases in vascular endothelial growth factor (VEGF) expression. [11, 12] However, in a small clinical study in 33 HCV-infected patients, viral load was not reduced during treatment, even among those who showed a tumor response; notably, VEGF levels were not measured. 
3. Understanding sorafenib efficacy and safety in advanced liver disease
The Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with SorafeNib (GIDEON) was initiated in 2009 as a global, prospective, post-marketing non-interventional study to further evaluate the safety of sorafenib in patients with unresectable HCC and CP B liver function. This study of more than 3000 patients was designed to assess a variety of patient subsets under real-life practice conditions.  At a second interim analysis in 2011, grade ≥3 AEs and drug-related serious AEs were similar across BCLC stages and were consistent with those reported in the SHARP and AP trials (i.e., hand-foot skin reaction [HFSR], diarrhea, fatigue). [15, 16] The GIDEON data are consistent with those from another study by Abou-Alfa and colleagues, who observed comparable AE rates in CP A and CP B patients with the exception of all-grade elevated bilirubin levels (67% vs 86%, respectively), grade ≥3 hyperbilirubinemia (14% vs 53%, respectively), and grade ≥3 encephalopathy (3% vs 13%, respectively). 
In both the GIDEON second interim analysis and the study by Abou-Alfa, patients with CP B status exhibited shorter median OS compared with patients with CP A, supporting the prognostic significance of this classification. [17, 18] Nonetheless, data suggest that CP B patients derive benefit from sorafenib. A retrospective study compared the outcomes of 148 patients with unresectable HCC treated with sorafenib to those of a similar cohort of 78 patients receiving best supportive care (BSC).  Sorafenib significantly extended the median OS over BSC in patients with CP A (11.3 vs 6.4 months, respectively;
4. Trials comparing sorafenib to other potential first-line agents in advanced HCC
The American Association for the Study of Liver Diseases (AASLD) recommends sorafenib for the treatment BCLC stage C disease,  and it remains the only approved systemic treatment for unresectable HCC. Although several other targeted therapies have been investigated, to date, none have improved on the outcomes of sorafenib in randomized controlled trials. Cheng and colleagues compared sunitinib and sorafenib in 1073 patients with advanced HCC similar to those in the SHARP and AP trials.  Although TTP was comparable, sorafenib-treated patients experienced significantly longer OS (10.0 vs 8.1 months;
|Sorafenib||BRAF, mutant BRAF, CRAF, FLT3, KIT, PDGFRβ, RET, VEGFR1, VEGFR2, VEGFR3 |
|Sunitinib||CSF1R, FLT3, PDGFRα, PDGFRβ, RET, VEGFR1, VEGFR2, VEGFR3, KIT |
|Brivanib||FGFR1, VEGFR |
|Linifanib||CSFR1, FLT3, KIT, PDGFRβ, VEGFR1, VEGFR3 |
|Dovitinib||CSFR1, FGFR1, FGFR2, FGFR3, FLT3, KIT, PDGFRβ, RET, TrkA, VEGFR1, VEGFR2, VEGFR3 |
|Nintedanib||FGFR1, FGFR2, FGFR3, FGFR4, PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3 |
It is remarkable that despite significant overlap in molecular target specificity— particularly the VEGF receptors (Table 2)— none of these agents have, as yet, demonstrated superior OS benefit compared with sorafenib. One explanation may be that a unique molecular activity of sorafenib accounts for its consistently improved benefit. For example, among these agents, sorafenib is the only reported inhibitor of BRAF; overexpression of Raf1 has been detected in 49-100% of HCC biopsies and is an independent risk factor for death [24, 25] (Table 2). It is also possible that tolerance of sorafenib is a factor in improving OS or that the clinical trial designs (e.g., dosing, patient criteria) were suboptimal for demonstrating comparator activity. Two additional agents, dovitinib and nintedanib (BIBF1120), which have significant activity against fibroblast growth factor receptor, are currently being evaluated as first-line agents in phase 2 trials (NCT01232296, NCT01004003).
5. Addressing HCC management dilemmas: Ongoing studies
The introduction of sorafenib has unveiled a number of new challenges in the real-world setting. Patient management is complicated by the concurrence of underlying hepatic dysfunction. Given the complexity of managing both liver cancer and hepatic impairment, the value of a multidisciplinary approach to HCC care has become increasingly apparent. Patients may have undergone or be candidates for procedures such as TACE, surgery, or radiofrequency ablation. Questions remain as to whether sorafenib use is safe and beneficial in these settings and when it should be used in the continuum of care. Similar questions arise in the context of transplantation. Compounding these scientific quandaries is the fact that these patients may initially be seen by surgeons or interventional radiologists, who typically do not prescribe oncology medications. By the time patients are evaluated by an oncologist or hepatologist, clinical deterioration may prohibit the initiation of sorafenib therapy. Moreover, while institutional standards exist with respect to implementation of these procedures, substantial regional variations occur, making clinical trial design difficult. Significant challenges persist in defining appropriate response guidelines (e.g., RECIST) for specific therapies  and in defining the role of sorafenib in the treatment of patients with HCC progression.
5.1. Combination with locoregional therapy
The rationale for combining sorafenib with TACE is to mitigate the VEGF surge in response to hypoxemia associated with embolization of the hepatic artery supplying the tumor. [27, 28] Because increased circulating VEGF post-TACE has been linked to more aggressive disease,  blocking angiogenesis following embolization is hypothesized to improve outcomes and provides rationale for further studies.
Two large placebo-controlled studies evaluated the efficacy and safety of sorafenib combined with TACE. The first trial (N=458) evaluated sorafenib in Japanese and Korean patients with unresectable HCC, good performance status (88% ECOG PS 0), preserved liver function (100% CP A), and prior radiologic response to TACE.  The median time from TACE to initiating treatment with sorafenib was 9.3 weeks. This interrupted sequencing did not significantly prolong OS or median TTP (5.4 and 3.7 months in the sorafenib and placebo groups, respectively). Hypothetically, the delay between TACE and sorafenib initiation and the relatively low daily dose of sorafenib (median 386 mg, range 112-794.5 mg) may have contributed to the lack of superiority for combined treatment. Notably, significant differences in outcomes were observed among patient groups stratified by geographic region, likely reflecting regional variations in HCC treatment.
Sorafenib may exert its greatest benefit when administered before or concurrent with TACE treatment. The second trial, Sorafenib or Placebo in combination with transarterial chemoembolization with doxorubicin-eluting beads for intermediate-stage HCC (SPACE), examined this strategy. This global phase 2 study randomized 307 patients (CP A, ECOG PS 0) with intermediate-stage HCC to TACE with doxorubicin-eluting beads (DEB-TACE) plus sorafenib or placebo. DEB-TACE was administered 3-7 days after initiating sorafenib or placebo and subsequently on the first day of cycles 3, 7, and 13, and every 6 cycles thereafter.  While TTP was similar between the DEB-TACE/sorafenib and DEB-TACE/placebo arms, interpretation of the results is limited by the study design (scheduled DEB-TACE treatments are not routinely employed in clinical practice) and challenges inherent with assessing response to locoregional therapies. A third, single-center, phase 2 randomized controlled study (N=80) examined TACE with or without sorafenib exclusively in HCV-infected patients.  In this study, in which sorafenib was administered 30 days after TACE, TTP was significantly delayed in the sorafenib-treated group (9.2 months vs 4.9 months;
Several additional trials are currently recruiting patients to evaluate the combined use of LRT and sorafenib. A phase 3 (N=412) TACE-2 trial (NCT01324076) is examining the benefit of initiating sorafenib treatment 2-5 weeks prior to DEB-TACE. Patients may undergo further TACE based on their clinician’s evaluation. Another phase 3 (N=400) trial, ECOG 1208 (NCT01004978), will also evaluate initiating sorafenib prior to TACE, with TACE treatment occurring every 4 weeks with up to 4 courses of treatment. In this trial, the TACE protocol may use conventional chemoembolization comprising doxorubicin hydrochloride only or DEB-TACE. Finally, the phase 3 (N=400) STOP-HCC trial (NCT01556490) is evaluating the use of radioembolization followed 30 days later by sorafenib (R. Salem, personal communication). The large number of trials assessing the combination of LRT with sorafenib attests to the perceived potential of this approach. However, the wide variations in trial design underscore the difficulties in evaluating the true benefit of this combination. Variations in the timing of sorafenib dosing and the type of LRT (conventional TACE, DEB-TACE, or radioembolization) and frequency employed, coupled with a lack of reliable standardized methods for evaluating response, make trial design and treatment decision-making very challenging.
5.2. Is there a potential role for adjuvant sorafenib?
Despite intervention with potentially curative resection or ablation, HCC recurrence remains at 15-20% annually, with the 5-year recurrence rate reaching 80–90%.  Addressing residual disease and preventing or delaying recurrence remain key unmet needs; proven adjuvant therapies do not yet exist. A phase 3 randomized, double-blind, placebo-controlled study of sorafenib as an adjuvant treatment after surgical resection or local ablation (STORM: NCT00692770) is underway. If sorafenib can substantially delay HCC recurrence, survival may be impacted in a clinically meaningful way.
5.3. Could neoadjuvant sorafenib facilitate surgery or transplantation?
Liver transplantation is the accepted best curative option for HCC patients meeting the Milan criteria. However, organ availability is limited, and in one study, dropout while on the waiting list was found to be the sole prognostic factor in patients selected for orthotopic liver transplantation (OLT).  Sorafenib may represent a potential “bridge” option for patients awaiting OLT. Evaluating the benefit of sorafenib treatment in the transplant setting faces many of the same hurdles as for TACE, especially with respect to when it should be used in the continuum of care. Using a sensitivity analysis, one study showed that neoadjuvant sorafenib improved survival over no therapy, providing a cost benefit in T2-HCC patients waiting for liver transplant for ≤6 months; however, further safety assessments in the pre-transplant population are needed. 
In a pilot cohort study (N=33) of patients undergoing liver transplantation for HCC, overall death rates were similar between sorafenib-treated patients and controls (20% vs 9%, respectively;
In another study, investigators reviewed 59 consecutive HCC patients (10 treated with sorafenib and 49 controls) who underwent liver transplantation at a single center and concluded that pre-transplant sorafenib did not increase the rate of surgical complications.  The frequency of post-transplant AEs, including biliary complications, strictures, wound infection, and bleeding, was similar in both groups.
Two case reports describe successful outcomes associated with sorafenib followed by curative treatment for HCC. In one report of two patients with locally advanced HCC with portal vein thrombosis (PVT), neoadjuvant sorafenib administered for 10 and 12 months, respectively, produced sufficient tumor shrinkage to reverse PVT, normalize alpha-fetoprotein (AFP), and enable curative surgical resection. In both patients, sorafenib was stopped one week prior to surgery without post-operative complications.  However, in the SHARP and AP trials, response rates were <5%; therefore, chances of consistently downsizing HCC are very slim, and multimodality therapies need to be studied in this setting. In another report, a patient with relapsed HCC following hepatic resection was treated for 5 months prior to salvage transplant without complications. Three months after transplant (at the time of the report), the patient had normal liver function and no evidence of recurrence. 
5.4. Sorafenib in the post-transplant setting
Only a few small studies have addressed treatment options for post-transplant HCC recurrence. Preliminary data from a phase 1 trial show that sorafenib treatment in high-risk HCC patients post-transplant is feasible, with no dose-limiting toxicities to date; 12 patients have received sorafenib (200 mg once daily [QD] escalating thus far to 400/200 mg QD) for a median 167 days (range 21-170 days) and 3 patients experienced HCC recurrence. 
In a retrospective case-controlled study of 17 patients outside Milan criteria who underwent OLT, adjuvant or palliative sorafenib was administered to 5 and 6 patients, respectively. Patients treated adjuvantly demonstrated significantly improved disease-free survival at 6 months (100% vs 37.5%,
In a single-center retrospective analysis of 24 patients with HCC recurrence post-transplant, treatment with sorafenib (N=8) for disseminated disease outside the liver produced a mean OS of 6.7 months (95% confidence interval [CI], 4.8-8.6).  These data require confirmation through further study with larger cohorts and a more rigorous trial design. A randomized phase 2 trial (N=356) of sorafenib versus placebo in high-risk patients after liver transplant (NCT01624285) is ongoing; 2-year recurrence-free survival (RFS) is the primary endpoint, with secondary endpoints of OS, safety, and RFS at 1 year.
5.5. Potential for combination with other targeted systemic therapies
Although sorafenib significantly improves OS in patients with advanced HCC, patients ultimately experience disease progression. Disease progression may result from the lack of inhibition of, or compensatory activation of, alternate signaling pathways that promote tumor regrowth. Adjunct treatment with other systemic agents may provide additive or synergistic effects. Table 3 summarizes several phase 2 and 3 trials examining combinations of sorafenib with inhibitors of HMG-CoA reductase, mTOR, and angiopoietins-1 and -2 in the first-line setting. SEARCH (Sorafenib and Erlotinib, a rAndomized tRial protocol for the treatment of patients with Hepatocellular carcinoma) (N=720) compared the efficacy of sorafenib plus the epidermal growth factor receptor inhibitor erlotinib with sorafenib alone. This trial did not achieve its primary endpoint of a 33% improvement in OS (9.5 vs 8.5 months,
|NCT01075555||Randomized Phase III Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of CP A Hepatocellular Carcinoma||Pravastatin||HMG-CoA reductase||OS/PFS, TTP, QOL|
|NCT01005199||Sorafenib Alone or in Combination With Everolimus in Patients With Unresectable Hepatocellular Carcinoma. A Randomized Multicenter Phase II Trial.||Everolimus||mTOR||PFS/OR, DS, PFS, TTP, OS|
|NCT01687673||Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma||Temsirolimus||mTOR||TTP/RR, PFS, OS, TTF|
|NCT01418729||Phase-II, Multicenter, Randomized, Double-Blind, Parallel-Group Trial to Compare the Efficacy and Safety of Sorafenib Plus Pravastatin Against Sorafenib Plus Placebo in Patients With Advanced Hepatocarcinoma||Pravastatin||HMG-CoA reductase||OS/TTP, TTSP|
|NCT00872014||Phase 2 Open-label Multi-Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or InoperableHepatocellular Carcinoma||AMG386||angiopoietins -1 and -2||PFS/OR,DCR,OS,TTP|
5.6. Sorafenib benefit in portal hypertension remains controversial
Preliminary data suggest a beneficial effect of sorafenib on portal hypertension (PHT) in patients with cirrhosis and HCC. [45, 46] Increased splanchnic circulation combined with increased hepatic vascular resistance and hyperperfusion are the principal mechanisms leading to PHT. Angiogenesis is crucial in mediating increased splanchnic blood flow, and the ability of sorafenib to inhibit angiogenesis may account for the observed effects. This finding may be most relevant in patients with an HCV etiology due to a higher frequency of coexisting cirrhosis and PHT, but additional studies are needed to confirm a benefit in this setting.
5.7. Optimization of sorafenib therapy and patient selection
Prognostic HCC staging may be used for (1) predicting survival; (2) guiding therapy decisions; and (3) stratifying patients in clinical trials. Unlike other cancers, risk factors and underlying chronic liver disease (CLD) in HCC patients may have a greater impact on OS than tumor biology. This syndrome of “two diseases” directly affects patient survival, which in turn influences prognostic stratification in clinical trials and clinical decision-making. Therefore, HCC staging systems generally consider multiple prognostic factors related to CLD status and tumor stage.
The CP score is the standard assessment for classifying liver function in HCC patients. BCLC tumor staging, which also serves as a treatment algorithm, is most commonly used in the US and Europe. BCLC staging is endorsed by the AASLD and the European Association for the Study of the Liver and is most commonly used in therapeutic decision-making and in clinical trials. The prognostic power of the BCLC and other staging systems may potentially be improved by incorporating criteria based on plasma concentrations of biologic factors related to liver reserve and tumor biology.
In clinical studies, plasma levels of angiopoietin-2,  VEGF, -  hepatic growth factor (HGF),  insulin-like growth factor (IGF)-1, [48, 51] and IGF-2  have shown prognostic value. In the SHARP study population, 10 plasma biomarkers implicated in HCC pathogenesis were measured in 491 patients at baseline and 305 patients after 12 weeks of treatment. VEGF and ang2 were found to be strong, independent predictors of survival.  Similar results were demonstrated in other studies in which elevated expression of angiopoietin-2  and upregulation of its mRNA [53, 54] in HCC tissues were associated with advanced pathologic features and poor outcome. Elevated HGF was also found to be indicative of poor prognosis, though its significance was not retained in multivariate modeling.  Kaseb et al have found that integrating plasma IGF-1 as an indicator of liver reserve and VEGF as a measure of tumor burden improves the prognostic stratification of BLCL stage C patients.  These results represent promising steps in improving patient stratification but will require further validation.
Biomarkers predicting response to sorafenib have yet to be identified. In the SHARP analysis, low baseline HGF or high baseline s-c-KIT levels were independent predictors of survival in sorafenib-treated patients but showed only a non-significant trend as predictors of response.  In another study, an AFP response (>20% decline over baseline) at 6 weeks was associated with improvements in clinical benefit and PFS, and marginally improved OS.  Ueshima et al reported that a ≥2-fold increase in serum des-γ-carboxyprothrombin (DCP) at 2 weeks was observed in HCC patients with significantly extended TTP (
Studies suggest that AEs occurring during sorafenib treatment may provide prognostic and predictive information. In a single-center prospective study of 40 Asian, predominantly HBV-positive patients with unresectable HCC, the presence of any AE was associated with longer OS than the absence of an AE (21.5 vs 7.6 months, respectively;
6. Perspective in the management of sorafenib-treated patients with HCC
When sorafenib treatment is initiated, several factors may be considered regarding dose selection, including age, ECOG PS, and status of underlying liver disease. Sorafenib should be continued until unacceptable toxicity or lack of clinical benefit is documented; this latter endpoint is challenged by the suboptimal tools available to assess response in HCC  and therefore relies heavily on the discretion of the treating physician. If a patient demonstrates radiologic progression only, sorafenib may be continued at least until symptomatic progression. In a recently published nonrandomized study (N=36), Miyahara et al found that metastatic tumor growth rates increased in patients who discontinued sorafenib after radiologic progression, but remained unchanged in patients who continued sorafenib. Survival beyond first radiologic progression was also significantly longer in patients who continued sorafenib.  In the SHARP trial, both clinical and radiologic assessments were performed; OS did not correlate with radiologic response, and patients continued sorafenib until both clinical and radiologic progression. It is important to note that symptomatic progression may be related to tumor growth and/or deteriorating liver status.
Management of side effects is critical for promoting uninterrupted treatment. It is well known that sorafenib is associated with skin reactions, diarrhea, and fatigue, but with proactive management and diligent follow-up in the early months of therapy, long-term treatment is feasible. HFSR often contributes to early discontinuation of sorafenib. In one study, the median onset of HFSR-associated symptoms was 18.4 days after initiating therapy (range 3-56 days).  A recent meta-analysis of 24 trials in patients with solid tumors reported a 9% incidence of high-grade HFSR in sorafenib-treated patients.  Prophylactic measures may minimize the onset and intensity of HFSR. A large, randomized, controlled phase 2 study (N=868) demonstrated that prophylaxis with urea-based cream over a 12-week period significantly reduced the incidence of all grades of HFSR compared to BSC in sorafenib-treated patients (56% vs 74%;
Sorafenib is an orally active multikinase inhibitor approved for the treatment of advanced, unresectable HCC. In randomized, double-blind, placebo-controlled, multicenter trials, sorafenib monotherapy prolonged median OS and delayed median TTP. With its acceptable safety profile and demonstrated survival benefit, sorafenib remains the only standard of care systemic therapy for unresectable HCC. However, additional trials of new molecules or combination therapy including sorafenib are needed to improve the outcomes of patients with unresectable HCC. Critical to HCC management is the establishment of surveillance programs to facilitate identification and referral in earlier-stage HCC, as well as the introduction of novel approaches to reducing the size of HCC tumors to increase the utilization and success of curative options such as resection or transplantation.
The authors acknowledge the medical writing and editorial support provided by Percolation Communications, LLC and funded by Onyx Pharmaceuticals, Inc. and Bayer Healthcare. Dr. Kaseb has received support from Bayer Healthcare and Onyx Pharmaceuticals, Inc. Dr. Kulik has received support from Bayer Healthcare and Nordion.